MedPath

A Comparison of XELOX Regimen and EOX Regimen as Neoadjuvant Chemotherapy Regimen for Locally Advanced Gastric Cancer.

Completed
Conditions
Locally Advanced Gastric Cancer
Registration Number
NCT02192983
Lead Sponsor
Tianshu Liu
Brief Summary

This study is designed to assess what is the better neoadjuvant chemotherapy regimen for patients with initially unresectable locally advanced gastric cancer.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
242
Inclusion Criteria
  • more than 2 regional bulky lymph nodes macroscopic tumor type is either the Borrmann type 4 or large type 3 tumor invades adjacent structures (T4b)
Exclusion Criteria
  • peritoneal metastasis confirmed by CT scan lung metastasis, liver metastasis, pleural effusion, and/or other distant metastasis

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Response rate6 months after diagnosis
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Shanghai Zhongshan Ethics Committee

🇨🇳

Shanghai, Shanghai, China

Shanghai Zhongshan Ethics Committee
🇨🇳Shanghai, Shanghai, China

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.